15.05.2012 | MOLOGEN AG: Promising start to 2012 business year - Quarterly report submitted
Phase II colorectal cancer study with MGN1703 confirms proof of conceptVery good data from phase I/II renal cancer study with MGN1601 Patent protection in other countries ... | more ...
Author/Copyright | MOLOGEN AG
03.05.2012 | Max-Delbrück-Centrum erhält Millionenförderung für ein Deutsch-Israelisches Doktoranden-Ausbildungsprogramm (Kopie 1)
The Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch has long standing collaborative relations with two top Israeli universities: Technion – Israel Institute of ... | more ...
Author/Copyright | Max Delbrück Center Wins EUR 1.8 Million Grant by ...
02.05.2012 | Gene Mutation Leads to Impairment of Two Senses: Touch and Hearing
People with good hearing also have a keen sense of touch; people with impaired hearing generally have an impaired sense of touch. Extensive data supporting this hypothesis was ... | more ...
Author/Copyright | Max-Delbrück-Centrum für Molekulare Medizin (MDC) ...
19.04.2012 | LGC Genomics invests in new laboratory in Boston, US
Stepping up investment in the US – LGC Genomics opens new DNA extraction and genotyping service lab in Boston, MA | more ...
Author/Copyright | LGC
04.04.2012 | NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2012 | more ...
Author/Copyright | NOXXON Pharma AG
Newsfeed as | RSS